Taiwan Reports Record Drug-Development Funds In First Half
This article was originally published in PharmAsia News
Taiwan reports $86.6 million worth of investments in development of new drugs by its drug makers during the first half of this year, 18 times more than the same period a year ago. The Industry and Technology Intelligence Service said the pharmaceutical portion of the biotechnology industry also invested heavily, registering an investment level of $169.6, nearly half the investments in the overall biotech industry. The ITIS also reported strong growth in exports of biotech products, including biomedical materials and antibodies. (Click here for more
You may also be interested in...
HONG KONG - Phase III clinical trials are slated to start next year on anti-cancer drug ADI-PEG 20 by U.S.-based Polaris Group's Taiwan subsidiary TDW Pharmaceuticals following successful Phase II trials that included recovery by a cancer patient deemed to have six months to live several years ago
New report shows average out-of-pocket cost per prescription of $10.67 in 2019 was unchanged from 2018. But while the number of dispensed drugs barely increased, sales jumped more than 5%.
The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.